A Clinical Study on the Impact of Hemoperfusion on the Prognosis of Uremic Patients Undergoing Maintenance Hemodialysis

Launched by XUJIAO CHEN · May 13, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to study the effects of a treatment called hemoperfusion on the health outcomes of patients with End-Stage Renal Disease (ESRD) who are receiving regular hemodialysis. Hemodialysis is a procedure that helps filter waste and excess fluids from the blood when the kidneys can no longer do so. The researchers want to see if adding hemoperfusion can improve how well these patients do overall.

To participate in this trial, individuals must be aged between 18 and 85 years and have been undergoing maintenance hemodialysis for at least three months. Participants will need to have a regular dialysis schedule of three times per week and should not have any significant remaining kidney function. However, those with certain serious health issues, like severe heart or lung problems, recent strokes, or certain infections, won't be eligible. If you or someone you know fits the criteria and is interested, you can expect to provide consent to participate and follow along with the study’s procedures. Keep in mind that this trial is not yet recruiting participants, so there will be more information available once it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing maintenance hemodialysis for ≥3 months Aged ≥18 years and \<85 years; Regular hemodialysis treatment, 3 times per week No residual renal function (urine output \<200 mL/d); Written informed consent has been obtained from the participant.
• Exclusion Criteria:
• • Patients with severe cerebrovascular diseases (new-onset cerebral infarction, cerebral hemorrhage) or neurological diseases (autoimmune encephalitis, epilepsy, neurodevelopmental disorders).
• • Patients with acute severe infections (such as sepsis), severe cardiopulmonary insufficiency (NYHA class IV heart failure, acute exacerbation of COPD), or malignancies.
• • Patients receiving combined hemodialysis and peritoneal dialysis treatment. Patients with allergic reactions, contraindications, or intolerance to dialysis membrane materials.
• • Patients with a platelet count \<60 × 10\^9/L. Other conditions deemed by the investigators as unsuitable for participation in this study.